UK approves Pfizer-BioNTech COVID-19 vaccine in world first


LONDON (Reuters) – Britain approved Pfizer Inc’s COVID-19 vaccine on Wednesday, jumping ahead of the rest of the world in the race to begin the most crucial mass inoculation programme in history.

Prime Minister Boris Johnson touted the green light from Britain’s medicine authority as a global win and a ray of hope for the end of the pandemic, though he recognised the logistical challenges of vaccinating an entire country of 67 million.

Britain’s move raised hopes that the tide could soon turn against a virus that has killed nearly 1.5 million people globally, hammered the world economy and upended normal life for billions since it emerged in Wuhan, China, a year ago.

Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) granted emergency use approval to the vaccine developed by Pfizer and German biotechnology partner BioNTech, which they say is 95% effective in preventing illness,

Read More

UK Approves Pfizer-BioNTech COVID-19 Vaccine, First in the World | Top News


By Guy Faulconbridge and Paul Sandle

LONDON (Reuters) – Britain approved Pfizer’s COVID-19 vaccine on Wednesday, jumping ahead of the United States and Europe to become the West’s first country to formally endorse a jab it said should reach the most vulnerable people early next week.

Prime Minister Boris Johnson touted the medicine authority’s approval as a global win and a ray of hope amid the gloom of the novel coronavirus which has killed nearly 1.5 million people globally, hammered the world economy and upended normal life.

Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) granted emergency use approval to the Pfizer-BioNTech vaccine, which they say is 95% effective in preventing illness, in record time – just 23 days since Pfizer published the first data from its final stage clinical trial.

“It’s fantastic,” Johnson said. “The vaccine will begin to be made available across the UK from next week. It’s

Read More

COVID-19 vaccine sprint as Pfizer-BioNTech, Moderna seek emergency EU approval


FRANKFURT (Reuters) – Moderna and Pfizer-BioNTech are in a tight race to launch their COVID-19 vaccines in Europe after both applied for emergency EU approval on Tuesday, though there was uncertainty over whether a rollout could begin this year.

The applications to the European Medicines Agency (EMA) came a day after Moderna sought emergency use for its shot in the United States and more than a week after Pfizer and BioNTech did the same.

U.S. drugmaker Pfizer and its German development partner BioNTech said their vaccine could be launched in the European Union as early as this month.

“We can start to deliver within a few hours (of an approval),” said Sierk Poetting, head of operations and finance at BioNTech. “We have been stocking up. And everything that is there can really be distributed within a few hours.”

The EMA clouded the timeline, however, when it said it would complete

Read More

Pfizer-BioNTech Seek EU Emergency Approval for COVID-19 Vaccine, Target December Rollout | Top News


FRANKFURT (Reuters) – Pfizer Inc and BioNTech’s COVID-19 vaccine could be rolled out in Europe this month, the companies said on Tuesday after they applied for EU emergency approval for the shot.

The application to the European Medicines Agency (EMA) comes days after the companies applied for emergency use of their vaccine in the United States. They said their candidate, BNT162b2, could be launched in the European Union this month.

“If EMA concludes that the benefits of the vaccine candidate outweigh its risks in protecting against COVID‑19, it will recommend granting a CMA (conditional marketing authorization)that could potentially enable use of BNT162b2 in Europe before the end of 2020,” they said in a joint statement.

In their pursuit of a European launch, the partners are neck-and-neck with rival Moderna, which said on Monday it would ask the EU regulator to recommend conditional approval for its shot.

An effective immunization is

Read More

Pfizer/BioNTech Seek First Vaccine Approval In US


US biotech giant Pfizer and German partner BioNTech sought approval Friday to roll out their coronavirus vaccine early, a first step towards relief as surging infections prompt a return to shutdowns that traumatized nations and the global economy earlier this year.

The world is looking to scientists for salvation from the global pandemic, as a new wave of infections forces New York to shut schools and California to implement night time curfews.

The US Food and Drug Administration (FDA) said its vaccines committee would meet on December 10 to discuss the request for emergency use authorization.

Vice President Mike Pence stands by a Covid-19 map during a White House Coronavirus Task Force press Vice President Mike Pence stands by a Covid-19 map during a White House Coronavirus Task Force press Photo: AFP / Brendan Smialowski

“The FDA recognizes that transparency and dialogue are critical for the public to have confidence in COVID-19 vaccines,” the organization’s head Stephen Hahn said in a statement.

“I want to assure the

Read More

Pfizer/BioNTech Seek Early Vaccine Approval As Second Virus Wave Hits Hard


US giant Pfizer and its German partner BioNTech confirmed they would seek approval on Friday to roll out their coronavirus vaccine early as surging infections forced New York to shut schools and California braced for nighttime curfews.

The world is looking to scientists for salvation from the global pandemic but a second wave of infections is prompting a return to the shutdowns and closures that traumatised nations and upturned the global economy at the start of the year.

The first tangible signs of relief could come Friday when Pfizer and BioNTech file an emergency use authorisation request with the US Food and Drug Administration.

Vice President Mike Pence stands by a Covid-19 map during a White House Coronavirus Task Force press Vice President Mike Pence stands by a Covid-19 map during a White House Coronavirus Task Force press Photo: AFP / Brendan Smialowski

“Our work to deliver a safe and effective vaccine has never been more urgent,” Pfizer chief executive Albert Bourla said. “Filing in the US

Read More

Pfizer/BioNTech Say Results Show Covid Vaccine 95% Effective


Pfizer and BioNTech said Wednesday a completed analysis of their experimental Covid-19 vaccine found it protected 95 percent of people against the disease and announced they were applying for US emergency approval “within days.”

The news from the US pharmaceutical company and its German partner brought further hope to a world upended by the coronavirus pandemic, and follows an announcement last week in which they said a preliminary analysis showed the product was 90 percent effective.

Adding to the encouraging data was that the efficacy was found to be consistent across all age-groups — a primary concern for a disease that hits the elderly the hardest — as well as genders and ethnicities.

“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” said Pfizer CEO Albert Bourla.

Wednesday’s news came after 170 people fell

Read More